Inventor · disambiguated record
Michael E. Perlman
Also filed as: PERLMAN MICHAEL · PERLMAN MICHAEL E
8 granted patents·4 pending applications·63 citations·filing 1982–2018
86Inventor score
Files withPFIZER3UNIV NEW YORK STATE RES FOUND3BEND RES INC2BECTON DICKINSON CO1CAMBRIDGE NEUROSCIENCE INC1
Top patents by PatentIndex Score
12 records- 0190US10357455B2Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materialsBEND RES INC·Filed 2018·Granted Jul 23, 2019·3 cites·12 claims
- 0279US9486410B2Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materialsPERLMAN MICHAEL E·Filed 2007·Granted Nov 8, 2016·3 cites·14 claims
- 0378US6962931B2Self-emulsifying formulations of cholesteryl ester transfer protein inhibitorsPFIZER·Filed 2002·Granted Nov 8, 2005·16 cites·4 claims
- 0464US4886790ANovel bis(2,2-dimethyl-1-aziridinyl) phosphinic amides for use in the treatment of tumorsUNIV NEW YORK STATE RES FOUND·Filed 1988·Granted Dec 12, 1989·9 cites·18 claims
- 0564US4544501ABis(2,2-dimethyl-1-aziridinyl)phosphinic amides for use in the treatment of tumorsUNIV NEW YORK STATE RES FOUND·Filed 1983·Granted Oct 1, 1985·10 cites·6 claims
- 0663US4617398APhosphoaziridine compounds useful for treatment of tumorsUNIV NEW YORK STATE RES FOUND·Filed 1982·Granted Oct 14, 1986·6 cites·8 claims
- 0763US2017000733A1Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materialsBEND RES INC·Filed 2016·Application pending·0 cites
- 0859US2003228358A1Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materialsPFIZER·Filed 2003·Application pending·0 cites
- 0946US4810631ASignal enhancement in immunoassay by modulation of chemical catalysisBECTON DICKINSON CO·Filed 1986·Granted Mar 7, 1989·15 cites·39 claims
- 1045US2006014788A1Self-emulsifying formulations of cholesteryl ester transfer protein inhibitorsPFIZER·Filed 2005·Application pending·0 cites
- 1144US2021023029A1Edasalonexent dosing regimen for treating muscular dystrophyCATABASIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1239US6774263B1Pharmaceutically active compound and methods of useCAMBRIDGE NEUROSCIENCE INC·Filed 1998·Granted Aug 10, 2004·1 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →